There is disclosed charge-modified conjugates comprising a targeting protein bound to a therapeutic or diagnostic agent. Charge-modifying a conjugate to cause an acidic shift in the isoelectric point results in prolonged serum half-life upon in vivo administration and is useful to accumulate a therapeutic...http://www.google.com.au/patents/US5635180?utm_source=gb-gplus-sharePatent US5635180 - Alteration of pharmacokinetics of proteins by charge modification
